Acute heart failure syndromes: Epidemiology, risk stratification and prognostic factors

References

• Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005; 112: 3958–68
   PubMed Web of Science ®Google Scholar
• Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007; 12: 87–90
   Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29: 2388–442
   PubMed Web of Science ®Google Scholar
• Ahmed A, Allman RM, Fonarow GC, Love TE, Zannad F, Dell'italia LJ, et al. Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail. 2008; 14: 211–8
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006c; 119(Suppl 1)S3–S10
   Google Scholar
• Adams KF, Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J. 2005; 149: 209–16
   PubMed Web of Science ®Google Scholar
• Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J. 2003; 24: 442–63
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50: 768–77
   PubMed Web of Science ®Google Scholar
• Fonarow GC. The acute decompensated heart failure national registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003; 4(Suppl 7)S21–30
   Google Scholar
• Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217–26
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008; 168: 847–54
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005; 96: 11G–7G
   PubMed Web of Science ®Google Scholar
• Beohar N, Erdogan AK, Lee DC, Sabbah HN, Kern MJ, Teerlink J, et al. Acute heart failure syndromes and coronary perfusion. J Am Coll Cardiol. 2008; 52: 13–6
   Google Scholar
• Felker GM, Leimberger JD, Califf RM, Cuffe MS, Massie BM, Adams KF, Jr, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004; 10: 460–6
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009; 53: 557–73
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis Stough W, Adams KF, Jr, Jaffe AS, Hasselblad V, O'Connor CM. The pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). Am J Cardiol. 2005; 96: 18G–25G
   PubMed Web of Science ®Google Scholar
• Adamson PB, Magalski A, Braunschweig F, Bohm M, Reynolds D, Steinhaus D, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003; 41: 565–71
   PubMed Web of Science ®Google Scholar
• Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of weight change preceding hospitalization for heart failure. Circulation 2007; 116: 1549–54
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963–71
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690–6
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Zimmer C, Burnett J, Grinfeld L, Maggioni AP, Swedberg K, et al. Relationship between body weight change following hospital discharge and risk for death/reshospitalization: an EVEREST analysis [abstract]. Eur Heart J. 2008; 29: 269
   Google Scholar
• Blair, JE, Khan, S, Konstam, MA, Grinfeld, L, Maggioni, AP, Swedberg, K, , et al. Weight changes after hospitalisation for worsening heart failure and subsequent re-hospitalisation and mortality in the EVEREST trial. Eur Heart J. 2009; .
   Google Scholar
• Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007; 28: 980–8
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med. 2007; 167: 1998–2005
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC, Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332–43
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC, Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA 2007; 297: 1319–31
   PubMed Web of Science ®Google Scholar
• Klein L, Massie BM, Leimberger JD, O'Connor CM, Pina IL, Adams KF, Jr, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: Results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF). Circ Heart Fail. 2008; 1: 1–8
   Google Scholar
• Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (ACTIV in CHF) study. J Card Fail. 2007; 13: 360–4
   PubMed Web of Science ®Google Scholar
• Blair J, Burnett JC, Konstam MA, Grinfeld L, Maggioni AP, Swedberg K, et al. Prognostic value and changes in renal function in patients admitted with acute heart failure- results from the EVEREST program [abstract]. Eur Heart J. 2008; 29: 270
   Google Scholar
• Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC, Jr, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 2008; 299: 2656–66
   PubMed Web of Science ®Google Scholar
• Bart BA, Shaw LK, McCants CB, Jr, Fortin DF, Lee KL, Califf RM, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997; 30: 1002–8
   PubMed Web of Science ®Google Scholar
• Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000; 342: 1077–84
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006; 114: 1202–13
   PubMed Web of Science ®Google Scholar
• Purek L, Laule-Kilian K, Christ A, Klima T, Pfisterer ME, Perruchoud AP, et al. Coronary artery disease and outcome in acute congestive heart failure. Heart 2006; 92: 598–602
   PubMed Web of Science ®Google Scholar
• Flaherty JD, Bax JJ, De Luca L, Rossi JS, Davidson CJ, Filippatos G, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol. 2009; 53: 254–63
   PubMed Web of Science ®Google Scholar
• Rossi JS, Flaherty JD, Fonarow GC, Nunez E, Gattis Stough W, Abraham WT, et al. Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: A report from OPTIMIZE-HF (organized program to initiate lifesaving treatment in hospitalized patients with heart failure). Eur J Heart Fail. 2008; 10: 1215–23
   PubMed Web of Science ®Google Scholar
• Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP multicenter study. J Am Coll Cardiol. 2007; 49: 1733–9
   PubMed Web of Science ®Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347: 161–7
   PubMed Web of Science ®Google Scholar
• Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126–30
   PubMed Web of Science ®Google Scholar
• Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008; 52: 347–56
   PubMed Web of Science ®Google Scholar
• O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Am Heart J. 2008; 156: 662–73
   PubMed Web of Science ®Google Scholar